Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
Two dental companies go public inside a week, with very different results.